Dyne Therapeutics Announces Pricing of $168 Million Public Offering

WALTHAM, Mass., Jan. 20, 2021 (GLOBE NEWSWIRE) — Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle illness company centered on advancing innovative existence-remodeling therapeutics for folks living with genetically driven diseases, recently announced the pricing of an underwritten public offering of 6,000,000 shares of its long-established stock at a public offering mark of $28.00 per fragment. Besides, Dyne has granted the underwriters a 30-day technique to snatch up to 900,000 extra shares of long-established stock at the public offering mark, much less the underwriting discount and commissions. The final shares are being supplied by Dyne.

The nasty proceeds of the offering, sooner than deducting the underwriting discount and commissions and diverse offering costs payable by Dyne, are expected to be roughly $168 million, with the exception of any train of the underwriters’ technique to snatch extra shares. The offering is expected to shut on Monday, January 25, 2021, field to previous closing stipulations.

J.P. Morgan, Jefferies, Piper Sandler and Stifel are acting as joint guide-operating managers for the offering.

A registration articulate pertaining to to the securities being purchased on this offering has been filed with, and declared effective by, the Securities and Alternate Payment. This offering is being made totally via a prospectus. Copies of the last prospectus pertaining to to this offering would possibly presumably per chance just be acquired, when accessible, from J.P. Morgan Securities LLC, c/o Broadridge Monetary Alternate choices, 1155 Long Island Avenue, Edgewood, Recent York 11717, via cell phone at (866) 803-9204 or via electronic mail at prospectus-eq_fi@jpmchase.com; Jefferies LLC, Consideration: Equity Syndicate Prospectus Division, 520 Madison Avenue, 2nd Flooring, Recent York, Recent York 10022, via cell phone at (877) 821-7388 or via electronic mail at Prospectus_Department@Jefferies.com; Piper Sandler & Co., Consideration: Prospectus Division, 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, via cell phone at (800) 747-3924 or via electronic mail at prospectus@psc.com; or Stifel, Nicolaus & Company, Incorporated, Consideration: Syndicate, One 1st viscount montgomery of alamein Boulevard, Suite 3700, San Francisco, California 94104, via cell phone at (415) 364-2720 or via electronic mail at syndprospectus@stifel.com.

This press beginning shall no longer constitute an provide to promote, or a solicitation of an provide to snatch, these securities, nor shall there be any provide or sale of these securities in any train or jurisdiction in which such provide, solicitation or sale would be unlawful before the registration or qualification below the securities licensed guidelines of this form of train or jurisdiction.

About Dyne Therapeutics

Dyne Therapeutics is building a main muscle illness company centered on advancing innovative existence-remodeling therapeutics for folks living with genetically driven diseases. The Company is utilizing its proprietary FORCE™ platform to beat the unusual limitations of muscle groups beginning with popular oligonucleotide therapeutic candidates. Dyne is increasing a ample portfolio of therapeutics for muscle diseases, in conjunction with capabilities in myotonic dystrophy model 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD).

Contact:

Dyne Therapeutics
Amy Reilly
areilly@dyne-tx.com
857-341-1203

Be taught More

LEAVE A REPLY

Please enter your comment!
Please enter your name here